OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr Maese on the Use of Pediatric-Inspired Regimens in AYA and Adult ALL

July 18th 2025

Luke Maese, DO, discusses how the evolution of AYA and adult ALL management may be inspired by treatment protocols used in the pediatric population.

Dr Kotecha on the Potential of ENPP3 as a Therapeutic Target in ccRCC

July 18th 2025

Ritesh R. Kotecha, MD, discusses the rationale for targeting ENPP3 in clear cell renal cell carcinoma.

Dr Sfakianos on Outcomes With Intravesical Mitomycin for Recurrent, Low-Grade, Intermediate-Risk NMIBC

July 18th 2025

John Sfakianos, MD, shared findings from an analysis of mitomycin intravesical solution from the phase 3 ENVISION trial in recurrent NMIBC.

Dr Sabari on Efficacy of Zidesamtinib in TKI-Pretreated, Advanced, ROS1+ NSCLC

July 18th 2025

Joshua K. Sabari, MD, discusses response rates observed with zidesamtinib in patients with advanced ROS1-positive non–small cell lung cancer.

Dr Runcie on Treatment Approaches in RCC After Progression on Adjuvant Therapy

July 18th 2025

Karie Danielle Keera Runcie, MD, discusses treatment challenges after progression on adjuvant therapy and the potential role for zanzalintinib in renal cell carcinoma.

Dr Powles on Results from a Q-TWiST Analysis of Belzutifan vs Everolimus in Previously Treated Advanced RCC

July 17th 2025

Thomas Powles, MD, discusses results from a Q-TWiST analysis of belzutifan vs everolimus in previously treated advanced renal cell carcinoma.

Dr Machaalani on the Potential Role of Circulating KIM-1 as a Biomarker in Metastatic RCC

July 17th 2025

Marc Machaalani, MD, discusses retrospective findings from a multi-platform analysis evaluating circulating KIM-1 as a biomarker in metastatic RCC.

Dr Duska on PFS2 Data With Pembrolizumab and Chemoradiotherapy in Cervical Cancer

July 17th 2025

Linda R. Duska, MD, MPH, discusses PFS2 data with pembrolizumab plus chemoradiotherapy in newly diagnosed, high-risk cervical cancer.

Dr Finn on Tiragolumab Plus Atezolizumab and Bevacizumab in HCC

July 17th 2025

Richard S. Finn, MD, discusses the background of the MORPHEUS-Liver trial of tiragolumab plus atezolizumab and bevacizumab in HCC.

Dr Hamilton on Unmet Needs for Brain Metastases in HER2+ Metastatic Breast Cancer

July 17th 2025

Erika P. Hamilton, MD, highlights the unmet needs regarding treatment for brain metastases in HER2-positive metastatic breast cancer.

Dr Eng on Real-World Outcomes in US Patients With KRAS G12C–Mutated CRC

July 16th 2025

Cathy Eng, MD, FACP, FASCO, discusses a real-world study of the effect of KRAS G12C mutations on outcomes in patients with metastatic colorectal cancer.

Dr Thaker on IMNN-001 Plus Neoadjuvant Chemo in Newly Diagnosed Ovarian Cancer

July 16th 2025

Premal H. Thaker, MD, MS, discusses data from a study of IMN-001 plus neoadjuvant chemotherapy in newly diagnosed epithelial ovarian cancer.

Dr Martini on the Evolving Role of Intravesical Therapies in High-Risk NMIBC

July 16th 2025

Alberto Martini, MD, discusses the evolving role of intravesical therapies in patients with high-risk non–muscle-invasive bladder cancer.

Dr Klempner on Data for Givastomig Plus Nivolumab/mFOLFOX in Metastatic Gastric, Esophageal, and GEJ Adenocarcinoma

July 16th 2025

Samuel J. Klempner, MD, discusses the safety and efficacy of givastomig plus nivolumab and chemotherapy in metastatic gastric cancers.

Dr Wilky on the Role of Personalized Therapy in GIST

July 16th 2025

Breelyn Wilky, MD, details personalized therapy approaches for the treatment of patients with GIST.

Dr Weinberg on the Implications of Data With BXCL701 Plus Pembrolizumab in mPDAC

July 15th 2025

Benjamin A. Weinberg, MD, FACP, discusses the clinical implications of data with BXCL701 plus pembrolizumab in metastatic pancreatic ductal adenocarcinoma.

Dr Mayadev on a ctDNA Analysis of the CALLA Trial in Cervical Cancer

July 15th 2025

Jyoti Mayadev, MD, discusses the value of ctDNA as a prognostic biomarker for relapse and survival in patients with locally advanced cervical cancer.

Dr McArthur on Monitoring for ILD When Administering T-DXd in HER2+ Breast Cancer

July 15th 2025

Heather McArthur, MD, discusses monitoring strategies for interstitial lung disease in patients with HER2-positive breast cancer treated with trastuzumab deruxtecan.

Dr Krishnan on Elranatamab Plus Daratumumab/Lenalidomide in Newly Diagnosed, Transplant-Ineligible Multiple Myeloma

July 15th 2025

Amrita Krishnan, MD, discusses data for elranatamab plus daratumumab and lenalidomide in newly diagnosed, transplant-ineligible multiple myeloma.

Dr Singhi on the Rationale for Evaluating Lurbinectedin Plus Atezolizumab in ES-SCLC

July 15th 2025

Eric K. Singhi, MD, explains the rationale for evaluating lurbinectedin plus atezolizumab as maintenance therapy after chemotherapy in ES-SCLC.